pentobarbital decreases outcomes of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of CYP3A4 inducers may well reduce sufentanil concentrations and efficacy, probably precipitating withdrawal syndrome in sufferers who have developed Bodily dependence to sufentanil. Discontinuation of concomitantly made use of CYP3A4 inducers may possibly raise sufentanil plasma focus.
pentobarbital will lessen the level or impact of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.
pentobarbital will reduce the extent or effect of bosentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
pentobarbital will lower the level or result of lapatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lessen the level or outcome of fruquintinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. If coadministration with average CYP3A4 inducers is unavoidable, keep on to administer fruquintinib at suggested dosage.
pentobarbital decreases levels of ponatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Stay away from Except if the coadministration outweighs the feasible threat of ponatinib underexposure; check for indications of diminished efficacy.
pentobarbital will lower the extent or influence of more info capivasertib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Robust or reasonable CYP3A inducers lower capivasertib publicity, which may minimize efficacy.
Medicines which have quantity limitations connected to each prescription. This restriction normally boundaries the quantity on the drug that will be coated.
pentobarbital will decrease the extent or impact of felodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Administer barbiturates with warning in individuals with hepatic hurt and at lessened doses initially; barbiturates shouldn't be administered to people showing the premonitory signs of hepatic coma
pentobarbital will minimize the extent or influence of bedaquiline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Stay away from coadministration of bedaquiline with powerful CYP3A4 inducers because of possible for decreased therapeutic outcome
pentobarbital will decrease the level or impact of tacrolimus by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
This drug may well interfere Along with the absorption of orally administered griseofulvin, reducing its blood stages; results of blood degree reduction unknown; preferable to avoid concomitant administration of such medicine
Monoamine oxidase inhibitors (MAOI) may possibly inhibit barbiturate metabolism and lengthen barbiturate consequences; keep track of carefully